Tom Steyer backs select biotech names

Billionaire investor Tom Steyer has highlighted a group of biotechnology companies as key opportunities, signaling strong confidence in the sector’s growth prospects. His views span several drug developers with recent regulatory milestones, as well as a major technology company with exposure to healthcare-related innovation.

Steyer’s bullish stance centers on Protagonist Therapeutics, Revolution Medicines, and other pharma-focused names, while Amazon.com (AMZN) is also included among his preferred holdings. The emphasis on these stocks reflects his outlook on both advanced therapeutics and the infrastructure that supports them.

Protagonist Therapeutics, Inc. ranks 4th on Steyer’s list of stock picks and is cited as having substantial upside potential. The company recently received U.S. Food and Drug Administration approval for Icotyde, a treatment for moderate-to-severe plaque psoriasis.

Icotyde is expected to compete in a market historically dominated by injectable biologic therapies. The approval positions Protagonist Therapeutics to participate more directly in this segment, which is a key reason the stock stands out in Steyer’s portfolio.

Steyer is also optimistic about Revolution Medicines, Inc., which has recently advanced its oncology pipeline. The company gained FDA approval for Daraxonrasib, a treatment for pancreatic cancer.

The approval of Daraxonrasib is viewed as an important development for Revolution Medicines’ market position. The stock features among the biotech names Steyer remains bullish on, underlining his interest in companies targeting serious and hard-to-treat cancers.

Amazon.com, Inc. appears as the 8th pick on Steyer’s list, and he is described as bullish on the stock with significant upside potential. While not a pure-play biotech company, Amazon is noted for benefits from its expanding cloud services and artificial intelligence revenue.

These capabilities support a range of data-intensive applications, including those used across healthcare and life sciences. Amazon’s presence on the list indicates Steyer’s view that technology infrastructure is an important part of the broader innovation landscape he is backing.

In addition to Protagonist Therapeutics and Revolution Medicines, Steyer’s attention extends to several other drug developers. Headlines reference his interest in Crinetics Pharmaceuticals, Liquidia Corporation, and BridgeBio Pharma.

Crinetics Pharmaceuticals is identified as a pharma stock Steyer likes, while Liquidia Corporation and BridgeBio Pharma are described as companies whose upside potential he admires. Together, these positions illustrate a diversified approach within the biotech and pharma space.

Across these holdings, Steyer’s stance is consistently characterized as bullish. The focus is on companies associated with newly approved therapies or perceived upside in areas such as psoriasis and pancreatic cancer, as well as on platforms enabling growth in cloud and AI services.

The combination of specialized biotech names and a large technology company suggests a strategy oriented around innovation-driven growth, anchored by recent FDA decisions and scaling digital infrastructure.